Fred J. Ansfield

[1][2] Ansfield co-founded the American Society of Clinical Oncology (ASCO) in 1964, along with Harry Bisel, Arnoldus Goudsmit, Herman H. Freckman, Robert W. Talley, William Wilson and Jane Cooke Wright.

After his internship and residency training at Milwaukee County Hospital, Ansfield became a camp physician for the Civilian Conservation Corps near Glidden, Wisconsin.

[6] During World War II, Ansfield served in the U.S. Army Medical Corps as a battalion surgeon for the 11th Airborne division in the Philippines and New Guinea.

[5] In 1952 Ansfield began discussing the idea of using the immune system in cancer therapy with his former medical school classmate, Dr. Harold Rusch, then head of the McArdle Memorial Laboratory at the University of Wisconsin.

[1] "It was just after he arrived here [Madison] that Dr. Ansfield proposed that dosages of a new drug, 5-Fluorouracil, be increased in the treatment of incurable cancer to find if it had more value than was generally believed".[6]"Dr.

He performed clinical trials to develop protocols that maximized the therapeutic actions of 5-FU while minimizing the drug’s damage to normal tissues.

[8] The American Society of Clinical Oncology's charitable organization, Conquer Cancer Foundation, granted a 'Fred J. Ansfield, MD Endowed Young Investigator Award' in 2017.